Replies to post #360731 on Anavex Life Sciences Corp (AVXL)

[jmvho]

Very nice analysis boi !

jmvho

[Jonjones325]

Great post. Wondering how you get approved for something like that.

It’s a great endgame. I’d imagine we would have to get approved for several neurodevelopmental diseases before that’s considered.

[nidan7500]

boi568

The first prong is not as obvious as the second. Aside from demonstrating Anavex's commitment to a platform-based pharmaceutical, it also indicates that the company's research shows the best treatment regime correlates according to symptom and biomarker, rather than by disease diagnosis. (Shades of Mayomobile's predictive matrix are appearing to me.) Put another way, I think this means that the company has found the dose-response curve to track symptoms and biomarkers better than diseases. This is consistent with the Anavex position that it has an upstream, platform-based solution acting above specific indications.

Brilliant assessment boi568 and follow up, thank you. The learning process must and will continue from here. IMO, Dr.M. is already working down-along these lines. In the meantime, many patients and their families will be involved in each process step, some may have a longer path than others. This, IMO, is at least civilized clinical-medical science w/an excellent focus with a true clinical knowledge blessing to follow. This is how work gets done. Brilliant leadership is required. We may even see a new CNS disease FDA start to contribute, IMO.

I am not qualified to assess any endpoints yet, but I do recognize a new standard of/for processing excellence . Thanks very much for your work. WGT.

[Investor2014]

One of the inclusion criteria for the Anavex Rett trials is classic RTT.

“Diagnosis of classic RTT, according to 2010 criteria (Neul et al., 2010), and a MECP2 mutation.”

Because of course one wants homogeneity in the clinical trial population not to confound the results with too many variables. One reason that enrollment particularly for a rare disease can take time.

[Boopka]

Boi, really well thought out post. Thank you.
Have you thought about running it through IR for their input?

[Steady_T]

Very interesting and thoughtful post. You have hit the nail on the head. Diagnostic criteria in most CNS diseases are based on symptomatic descriptions rather than biometric criteria. Those symptoms have been shown to have a multiple of underlying biological causes resulting in the same or very similar symptoms. A very similar situation has been discovered in cancers. What appeared to be similar cancers in the same region of tissues has been found to be a result of different biochemical and genetic pathways, And of course have need a different treatment approach.

Anavex 2-73 being an upstream approach to treatment may well be a more general pathway treatment than previously attempted treatments. Will it be the ultimate treatment for these CNS disease? I think not. Will it be a paradigm changing approach to CNS treatments, that seems to be a high likelihood.

Additional drugs will come down the pike based on the new paradigm demonstrated by 2-73. They will be more specifically targeted than 2-73. But who knows. 2-73 or 3-71 may become the aspirin of CNS or as we have hoped a general old age tonic.

[Pipilongstocking]

Thanks, interesting.

[abew4me]

Quote: "I think this new neurodevelopmental patent application serves two purposes. First, it redefines the medical use of 2-73 on the basis of symptoms and biomarkers, rather than disease names. Second, it restarts the full patent protection clock on the medical use of 2-73 for this category of diseases.

Hello, 2040's."

Hmm...me thinks the Millionaires List is going to be quite large next year!

[tradeherpete]

Boi, Thanks for actually reading the new patent application and also, for the analysis.

The first prong is not as obvious as the second. Aside from demonstrating Anavex's commitment to a platform-based pharmaceutical, it also indicates that the company's research shows the best treatment regime correlates according to symptom and biomarker, rather than by disease diagnosis. (Shades of Mayomobile's predictive matrix are appearing to me.) Put another way, I think this means that the company has found the dose-response curve to track symptoms and biomarkers better than diseases. This is consistent with the Anavex position that it has an upstream, platform-based solution acting above specific indications.

Second, if Anavex is preparing the scientific methods for medical treatment for neurodevelopmental disease through this patent, anyone else selling the pharmaceutical will inevitably fall within its scope of the 2-73 neurodevelopmental medical manual. Every year of patent protection is golden.

The Neurodevelpmental Manual. Nice one!

Anavex has begun an ambitious journey with this Patent Application.

https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220220142968%22.PGNR.&OS=DN/20220142968&RS=DN/20220142968

Looking forward to the MedCram Video.

[boi568]

FYI, the post I am responding to gives my thoughts on that interesting patent application from 2022.